Intravenous Iron Administration and Hypophosphatemia in Clinical Practice
المؤلفون المشاركون
المصدر
International Journal of Rheumatology
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-04-27
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Introduction.
Parenteral iron formulations are frequently used to correct iron deficiency anemia (IDA) and iron deficiency (ID).
Intravenous formulation efficacy on ferritin and hemoglobin level improvement is greater than that of oral formulations while they are associated with lower gastrointestinal side effects.
Ferric carboxymaltose- (FCM-) related hypophosphatemia is frequent and appears without clinical significance.
The aim of this study was to assess the prevalence, duration, and potential consequences of hypophosphatemia after iron injection.
Patients and Methods.
The medical records of all patients who underwent parenteral iron injection between 2012 and 2014 were retrospectively reviewed.
Pre- and postinjection hemoglobin, ferritin, plasma phosphate, creatinine, and vitamin D levels were assessed.
Patients who developed moderate (range: 0.32–0.80 mmol/L) or severe (<0.32 mmol/L) hypophosphatemia were questioned for symptoms.
Results.
During the study period, 234 patients received iron preparations but 104 were excluded because of missing data.
Among the 130 patients included, 52 received iron sucrose (FS) and 78 FCM formulations.
Among FS-treated patients, 22% developed hypophosphatemia versus 51% of FCM-treated patients, including 13% who developed profound hypophosphatemia.
Hypophosphatemia severity correlated with the dose of FCM ( p = 0.04 ) but not with the initial ferritin, hemoglobin, or vitamin D level.
Mean hypophosphatemia duration was 6 months.
No immediate clinical consequence was found except for persistent fatigue despite anemia correction in some patients.
Conclusions.
Hypophosphatemia is frequent after parenteral FCM injection and may have clinical consequences, including persistent fatigue.
Further studies of chronic hypophosphatemia long-term consequences, especially bone assessments, are needed.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Hardy, S.& Vandemergel, Xavier. 2015. Intravenous Iron Administration and Hypophosphatemia in Clinical Practice. International Journal of Rheumatology،Vol. 2015, no. 2015, pp.1-6.
https://search.emarefa.net/detail/BIM-1066885
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Hardy, S.& Vandemergel, Xavier. Intravenous Iron Administration and Hypophosphatemia in Clinical Practice. International Journal of Rheumatology No. 2015 (2015), pp.1-6.
https://search.emarefa.net/detail/BIM-1066885
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Hardy, S.& Vandemergel, Xavier. Intravenous Iron Administration and Hypophosphatemia in Clinical Practice. International Journal of Rheumatology. 2015. Vol. 2015, no. 2015, pp.1-6.
https://search.emarefa.net/detail/BIM-1066885
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1066885
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر